Immunoglobulins for Intravenous Use Inhibit TNFα Cytotoxicity In Vitro
Intravenous immunoglobulins (IVIg) have been used as an immunomodulatory therapy in a variety of diseases. Several mechanisms of action have been proposed, one of which is interference with the cytokine network. We have investigated the effect of IVIg on the cytotoxicity of human TNFα. IVIg was capa...
Gespeichert in:
| Veröffentlicht in: | Immunological investigations 1997-01, Vol.26 (5-7), p.569-578 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 578 |
|---|---|
| container_issue | 5-7 |
| container_start_page | 569 |
| container_title | Immunological investigations |
| container_volume | 26 |
| creator | Stangel, M. Schumacher, H. C. Ruprecht, K. Boegner, F. Marx, P. |
| description | Intravenous immunoglobulins (IVIg) have been used as an immunomodulatory therapy in a variety of diseases. Several mechanisms of action have been proposed, one of which is interference with the cytokine network. We have investigated the effect of IVIg on the cytotoxicity of human TNFα. IVIg was capable of protecting L929 fibroblasts from TNFα induced cell death. This effect was not species specific and was mediated by both the Fc and the Fab portion of immunoglobulins. Since the effect was also seen when IVIg was added after the removal of TNFα from the culture medium, it seems to be independent of the interaction of TNFα with its receptor. We conclude that IVIg either act on some point of the TNFα signalling pathway or influence the cell cycle unspecifically. The cytoprotective effect of IVIg potentially could contribute to the beneficial effect described for various diseases. |
| doi_str_mv | 10.3109/08820139709088541 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16310936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16310936</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-a57c1d9f2743f1c4d5047e27bf7e207d1475f4a78d692f63e054285ba4c227223</originalsourceid><addsrcrecordid>eNqFkM1KxDAUhYMoOv48gAuhK3fV_DYTdCODowOiG3Vb0jRxIm2jSarOY_kiPpMpMwgi6ubmhvOdw-UAsI_gEUFQHMPxGENEBIcirYyiNTBCjOCcEoTWwWjQ8wHYAtshPEIICSvEJtgURAgE4QhczNq279xD46q-sV3IjPPZrItevujO9SG7Czr957ayMbu9nn68Z5NFdNG9WWXjIknZvY3e7YINI5ug91bvDribnt9OLvOrm4vZ5OwqV5TgmEvGFaqFwZwSgxStGaRcY16ZNCGvEeXMUMnHdSGwKYiGjOIxqyRVGHOMyQ44XOY-effc6xDL1galm0Z2Op1bckEZ4hT-C6JiaJAUCURLUHkXgtemfPK2lX5RIlgOTPmj5eQ5WIX3VavrL8eq1qSfLnXbpT5b-ep8U5dRLhrnjZedsmGI_j3-5Jt9rmUT50p6XT663nep4D-O-wRD9Jwm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16310936</pqid></control><display><type>article</type><title>Immunoglobulins for Intravenous Use Inhibit TNFα Cytotoxicity In Vitro</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Stangel, M. ; Schumacher, H. C. ; Ruprecht, K. ; Boegner, F. ; Marx, P.</creator><creatorcontrib>Stangel, M. ; Schumacher, H. C. ; Ruprecht, K. ; Boegner, F. ; Marx, P.</creatorcontrib><description>Intravenous immunoglobulins (IVIg) have been used as an immunomodulatory therapy in a variety of diseases. Several mechanisms of action have been proposed, one of which is interference with the cytokine network. We have investigated the effect of IVIg on the cytotoxicity of human TNFα. IVIg was capable of protecting L929 fibroblasts from TNFα induced cell death. This effect was not species specific and was mediated by both the Fc and the Fab portion of immunoglobulins. Since the effect was also seen when IVIg was added after the removal of TNFα from the culture medium, it seems to be independent of the interaction of TNFα with its receptor. We conclude that IVIg either act on some point of the TNFα signalling pathway or influence the cell cycle unspecifically. The cytoprotective effect of IVIg potentially could contribute to the beneficial effect described for various diseases.</description><identifier>ISSN: 0882-0139</identifier><identifier>EISSN: 1532-4311</identifier><identifier>DOI: 10.3109/08820139709088541</identifier><identifier>PMID: 9399100</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Cell Cycle ; Cell Death ; Cell Line ; Cytotoxicity, Immunologic - drug effects ; Humans ; Immunoglobulin Fab Fragments - immunology ; Immunoglobulin Fc Fragments - immunology ; Immunoglobulins, Intravenous - pharmacology ; Neutralization Tests ; Receptors, Tumor Necrosis Factor - immunology ; Signal Transduction ; Tumor Necrosis Factor-alpha - immunology</subject><ispartof>Immunological investigations, 1997-01, Vol.26 (5-7), p.569-578</ispartof><rights>1997 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-a57c1d9f2743f1c4d5047e27bf7e207d1475f4a78d692f63e054285ba4c227223</citedby><cites>FETCH-LOGICAL-c432t-a57c1d9f2743f1c4d5047e27bf7e207d1475f4a78d692f63e054285ba4c227223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/08820139709088541$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/08820139709088541$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,59628,59734,60417,60523,61202,61237,61383,61418</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9399100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stangel, M.</creatorcontrib><creatorcontrib>Schumacher, H. C.</creatorcontrib><creatorcontrib>Ruprecht, K.</creatorcontrib><creatorcontrib>Boegner, F.</creatorcontrib><creatorcontrib>Marx, P.</creatorcontrib><title>Immunoglobulins for Intravenous Use Inhibit TNFα Cytotoxicity In Vitro</title><title>Immunological investigations</title><addtitle>Immunol Invest</addtitle><description>Intravenous immunoglobulins (IVIg) have been used as an immunomodulatory therapy in a variety of diseases. Several mechanisms of action have been proposed, one of which is interference with the cytokine network. We have investigated the effect of IVIg on the cytotoxicity of human TNFα. IVIg was capable of protecting L929 fibroblasts from TNFα induced cell death. This effect was not species specific and was mediated by both the Fc and the Fab portion of immunoglobulins. Since the effect was also seen when IVIg was added after the removal of TNFα from the culture medium, it seems to be independent of the interaction of TNFα with its receptor. We conclude that IVIg either act on some point of the TNFα signalling pathway or influence the cell cycle unspecifically. The cytoprotective effect of IVIg potentially could contribute to the beneficial effect described for various diseases.</description><subject>Cell Cycle</subject><subject>Cell Death</subject><subject>Cell Line</subject><subject>Cytotoxicity, Immunologic - drug effects</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - immunology</subject><subject>Immunoglobulin Fc Fragments - immunology</subject><subject>Immunoglobulins, Intravenous - pharmacology</subject><subject>Neutralization Tests</subject><subject>Receptors, Tumor Necrosis Factor - immunology</subject><subject>Signal Transduction</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><issn>0882-0139</issn><issn>1532-4311</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1KxDAUhYMoOv48gAuhK3fV_DYTdCODowOiG3Vb0jRxIm2jSarOY_kiPpMpMwgi6ubmhvOdw-UAsI_gEUFQHMPxGENEBIcirYyiNTBCjOCcEoTWwWjQ8wHYAtshPEIICSvEJtgURAgE4QhczNq279xD46q-sV3IjPPZrItevujO9SG7Czr957ayMbu9nn68Z5NFdNG9WWXjIknZvY3e7YINI5ug91bvDribnt9OLvOrm4vZ5OwqV5TgmEvGFaqFwZwSgxStGaRcY16ZNCGvEeXMUMnHdSGwKYiGjOIxqyRVGHOMyQ44XOY-effc6xDL1galm0Z2Op1bckEZ4hT-C6JiaJAUCURLUHkXgtemfPK2lX5RIlgOTPmj5eQ5WIX3VavrL8eq1qSfLnXbpT5b-ep8U5dRLhrnjZedsmGI_j3-5Jt9rmUT50p6XT663nep4D-O-wRD9Jwm</recordid><startdate>19970101</startdate><enddate>19970101</enddate><creator>Stangel, M.</creator><creator>Schumacher, H. C.</creator><creator>Ruprecht, K.</creator><creator>Boegner, F.</creator><creator>Marx, P.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19970101</creationdate><title>Immunoglobulins for Intravenous Use Inhibit TNFα Cytotoxicity In Vitro</title><author>Stangel, M. ; Schumacher, H. C. ; Ruprecht, K. ; Boegner, F. ; Marx, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-a57c1d9f2743f1c4d5047e27bf7e207d1475f4a78d692f63e054285ba4c227223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Cell Cycle</topic><topic>Cell Death</topic><topic>Cell Line</topic><topic>Cytotoxicity, Immunologic - drug effects</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - immunology</topic><topic>Immunoglobulin Fc Fragments - immunology</topic><topic>Immunoglobulins, Intravenous - pharmacology</topic><topic>Neutralization Tests</topic><topic>Receptors, Tumor Necrosis Factor - immunology</topic><topic>Signal Transduction</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stangel, M.</creatorcontrib><creatorcontrib>Schumacher, H. C.</creatorcontrib><creatorcontrib>Ruprecht, K.</creatorcontrib><creatorcontrib>Boegner, F.</creatorcontrib><creatorcontrib>Marx, P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Immunological investigations</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stangel, M.</au><au>Schumacher, H. C.</au><au>Ruprecht, K.</au><au>Boegner, F.</au><au>Marx, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunoglobulins for Intravenous Use Inhibit TNFα Cytotoxicity In Vitro</atitle><jtitle>Immunological investigations</jtitle><addtitle>Immunol Invest</addtitle><date>1997-01-01</date><risdate>1997</risdate><volume>26</volume><issue>5-7</issue><spage>569</spage><epage>578</epage><pages>569-578</pages><issn>0882-0139</issn><eissn>1532-4311</eissn><abstract>Intravenous immunoglobulins (IVIg) have been used as an immunomodulatory therapy in a variety of diseases. Several mechanisms of action have been proposed, one of which is interference with the cytokine network. We have investigated the effect of IVIg on the cytotoxicity of human TNFα. IVIg was capable of protecting L929 fibroblasts from TNFα induced cell death. This effect was not species specific and was mediated by both the Fc and the Fab portion of immunoglobulins. Since the effect was also seen when IVIg was added after the removal of TNFα from the culture medium, it seems to be independent of the interaction of TNFα with its receptor. We conclude that IVIg either act on some point of the TNFα signalling pathway or influence the cell cycle unspecifically. The cytoprotective effect of IVIg potentially could contribute to the beneficial effect described for various diseases.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>9399100</pmid><doi>10.3109/08820139709088541</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0882-0139 |
| ispartof | Immunological investigations, 1997-01, Vol.26 (5-7), p.569-578 |
| issn | 0882-0139 1532-4311 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16310936 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Cell Cycle Cell Death Cell Line Cytotoxicity, Immunologic - drug effects Humans Immunoglobulin Fab Fragments - immunology Immunoglobulin Fc Fragments - immunology Immunoglobulins, Intravenous - pharmacology Neutralization Tests Receptors, Tumor Necrosis Factor - immunology Signal Transduction Tumor Necrosis Factor-alpha - immunology |
| title | Immunoglobulins for Intravenous Use Inhibit TNFα Cytotoxicity In Vitro |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T06%3A03%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunoglobulins%20for%20Intravenous%20Use%20Inhibit%20TNF%CE%B1%20Cytotoxicity%20In%20Vitro&rft.jtitle=Immunological%20investigations&rft.au=Stangel,%20M.&rft.date=1997-01-01&rft.volume=26&rft.issue=5-7&rft.spage=569&rft.epage=578&rft.pages=569-578&rft.issn=0882-0139&rft.eissn=1532-4311&rft_id=info:doi/10.3109/08820139709088541&rft_dat=%3Cproquest_cross%3E16310936%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16310936&rft_id=info:pmid/9399100&rfr_iscdi=true |